In the current study, we demonstrate that MELK/EZH2/NF-κB signaling, activated in human high-grade gliomas, represents a key functional hallmark of GSCs and results in the poor prognosis of GBM patients. This evidence concerns the gene EZH2 and central nervous system cancer.